W. Putnam

发表

Use of Quantitative Pharmacology in the Development of HAE1, a High-Affinity Anti-IgE Monoclonal Antibody

H. Lowman, A. Joshi, Y. Deniz, 2008, The AAPS Journal.

Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy

M. Eisner, J. Matthews, R. Zhu, 2013, The AAPS Journal.

Pharmacokinetics and Exposure-Efficacy Relationships of Omalizumab in Patients with Nasal Polyps.

T. Omachi, R. Schoemaker, Angelica L. Quartino, 2021, Pulmonary pharmacology & therapeutics.

Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration

T. Singer, D. Danilenko, F. Theil, 2012, mAbs.

Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies

S. Prabhu, D. Baker, S. Iyer, 2012, mAbs.

Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies.

Yow-Ming C Wang, S. Prabhu, M. Subramanyam, 2010, Trends in biotechnology.

Population repeated time‐to‐event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires

Robin J. Svensson, M. Karlsson, J. Ribbing, 2021, CPT: pharmacometrics & systems pharmacology.

Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma

Robin J. Svensson, Jin Y. Jin, J. Ribbing, 2021, Journal of clinical pharmacology.

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.

E. Kerwin, Karl Yen, J. Matthews, 2018, Respiratory medicine.

Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)

P. Kuna, S. Szefler, S. Zielen, 2022, Clinical and translational allergy.

OX40L blockade and allergen-induced airway responses in subjects with mild asthma

S. Mosesova, P. O'Byrne, D. Cockcroft, 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials

R. Maciuca, P. Korenblat, N. Hanania, 2014 .

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge

N. Jarjour, J. Matthews, J. Arron, 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

R. Maciuca, P. Korenblat, N. Hanania, 2015, Thorax.

Translational and pharmacokinetic‐pharmacodynamic application for the clinical development of GDC‐0334, a novel TRPA1 inhibitor

Simon S. Gao, B. Liederer, P. Belloni, 2021, Clinical and translational science.

Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells.

L. Benet, L. Takahashi, S. Ramanathan, 2002, Journal of pharmaceutical sciences.

Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production

R. Maciuca, L. Boulet, P. O'Byrne, 2014, Science Translational Medicine.

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.

S. Mosesova, P. Korenblat, J. Matthews, 2013, The Journal of allergy and clinical immunology.

The effect of induction conditions and MDR1 genotypes on dicloxacillin pharmacokinetics

L. Benet, W. Putnam, D. Desai, 2003 .

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.

E. Bateman, A. Yokoyama, P. Korenblat, 2016, The Lancet. Respiratory medicine.

Efficacy and safety of lebrikizumab (an anti‐IL‐13 monoclonal antibody) in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo‐controlled phase II trial (TREBLE)

C. Flohr, T. Omachi, T. Bieber, 2018, Journal of the American Academy of Dermatology.

Comparison of Bidirectional Cephalexin Transport Across MDCK and Caco-2 Cell Monolayers: Interactions with Peptide Transporters

L. Benet, L. Takahashi, Lin Pan, 2004, Pharmaceutical Research.

Effect of the MDR1 C3435T Variant and P‐Glycoprotein Induction on Dicloxacillin Pharmacokinetics

L. Benet, Yong Huang, J. Woo, 2005, Journal of clinical pharmacology.

Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.

J. Matthews, C. Holweg, R. Zhu, 2017, Pulmonary pharmacology & therapeutics.

A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)

E. Israel, M. Solon, G. Gauvreau, 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Comparability Considerations and Challenges for Expedited Development Programs for Biological Products

S. J. Schrieber, Steven W. Martin, E. Chow, 2020, Drugs in R&D.

Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy

M. Eisner, J. Matthews, D. D’Argenio, 2013, The AAPS Journal.

Quantitative structure-pharmacokinetic parameters relationships (QSPKR) analysis of antimicrobial agents in humans using simulated annealing k-nearest-neighbor and partial least-square analysis methods.

Alexander Tropsha, Yunde Xiao, A. Tropsha, 2004, Journal of pharmaceutical sciences.

A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers

P. Belloni, Han Ting Ding, Jianshuang Wang, 2017, Advances in Therapy.

Treatment With MEMP1972A, An Anti-M1 Prime Monoclonal Antibody, Reduced Serum IgE In Healthy Volunteers And Patients With Allergic Rhinitis

R. Maciuca, J. Matthews, Jeffrey M Harris, 2012, Asian Test Symposium.